PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
Status:
Completed
Trial end date:
2019-08-05
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of multitargeted tyrosine kinase
inhibitor PLX3397 (PLX3397) when given together with radiation therapy and antihormone
therapy in treating patients with prostate cancer that is at intermediate or high risk of
spreading. Multitargeted tyrosine kinase inhibitor PLX3397 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth, and may also help the radiation
therapy work better. Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens
can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide
acetate, goserelin acetate, or degarelix, may lessen the amount of androgens made by the
body. Giving multitargeted tyrosine kinase inhibitor PLX3397 with radiation therapy and
antihormone therapy may be a better treatment for prostate cancer.